A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

For the first time in a decade, U.S. obesity rates have begun to decline, raising hopes that the nation may be turning a ...

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

Obese mice whose fat cells were genetically altered to produce an increased amount of the glucose-dependent insulinotropic ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

Researchers from Kumamoto University have identified a liver-derived protein, serine protease inhibitor A1 (SerpinA1), as a ...

Nov. 26, 2024 — Tirzepatide, a new injectable weight-loss drug, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with ...

In a new study, using a ventilator-on-a-chip model, researchers ... Sep. 12, 2024 — Researchers examined the impact of obesity in relation to treatment and mortality from data on over 500,000 ...

Eli Lilly has launched a new website-based access programme for some drugs like its new obesity therapy Zepbound, opening up a new direct-to-consumer (DTC) channel that could shake up how the ...

The two companies are in hot pursuit of Novo Nordisk and Eli Lilly, currently pioneering a new wave of obesity therapies ... dose of survodutide discontinued treatment, mainly due to ...

Obesity is a severe public health problem, contributing significantly to the global non-communicable disease burden, ...